The hospitalist at Memorial Sloan Kettering Cancer Center discussed what she believes is most important for practicing oncologists to understand about a study of 177Lu-DOTATATE in well-differentiated, high-grade neuroendocrine tumors.
In a study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, investigators evaluated responses and outcomes for patients with well-differentiated, high-grade neuroendocrine tumors (NETs) who were treated with 177Lu-DOTATATE (Lutathera).
Overall, the investigators observed a meaningful disease control rate of 69% during treatment with 177Lu-DOTATATE. Moreover, over half of patients received all 4 cycles of treatment, with treatment-related toxicities largely consisting of bone-marrow related events.
In an interview with CancerNetwork®, Kelley Lauren Coffman, MD, a hospitalist at Memorial Sloan Kettering Cancer Center, highlighted what she believes is most important for practicing oncologists to know about this study.
One important takeaway is that this therapy is available. It’s new. It’s a different type of therapy that’s generally used in neuroendocrine tumors. It is approved for [patients with] neuroendocrine tumors who have advanced metastatic analogues. And even in our patient population with higher-grade tumors, there can be benefit.
Coffman KL, Bodei L, Le T, et al. Treatment response and clinical outcomes of well-differentiated high-grade neuroendocrine tumors to 177Lu-DOTATATE. J Clin Oncol. 2021;39(suppl 3). Abstract #: 368.